Table 3.
Five-year overall survival and 95% confidence interval according to different LN staging.
| Staging systems | N (%) | OR (95 % CI) | 5-year OS (%) |
|---|---|---|---|
| AJCC 8th N stage (3) | |||
| pN0 | 34,024 (60.0) | 1.00 (Reference) | 87.2 |
| pN1a | 6,975 (12.3) | 2.06 (1.95–2.17) | 75.2 |
| pN1b | 7,149 (12.6) | 2.76 (2.63–2.90) | 68.1 |
| pN2a | 4,764 (8.4) | 3.82 (3.63–4.02) | 58.3 |
| pN2b | 3,835 (6.8) | 5.80 (5.52–6.10) | 44.1 |
| LNR, Berger et al. (16) | |||
| LNR1 | 36,041 (63.5) | 1.00 (Reference) | 86.9 |
| LNR2 | 10,058 (17.7) | 2.26 (2.16–2.36) | 72.4 |
| LNR3 | 5,594 (9.9) | 3.34 (3.19–3.51) | 61.3 |
| LNR4 | 5,054 (8.9) | 5.62 (5.38–5.88) | 44.3 |
| LNR, Rosenberg et al. (17) | |||
| LNR0 | 34,024 (60.0) | 1.00 (Reference) | 87.2 |
| LNR1 | 11,520 (20.3) | 2.41 (2.05–2.24) | 74.1 |
| LNR2 | 6,659 (11.7) | 3.44 (3.29–3.61) | 61.3 |
| LNR3 | 2,919 (5.1) | 5.06 (4.78–5.35) | 48.9 |
| LNR4 | 1,625 (2.9) | 7.99 (7.49–8.53) | 33.0 |
| LODDS, Wang et al. (26) | |||
| LODDS1 | 3,707 (6.5) | 1.00 (Reference) | 91.0 |
| LODDS2 | 29,557 (52.1) | 1.57 (1.41–1.75) | 86.5 |
| LODDS3 | 19,761 (34.8) | 3.84 (3.45–4.27) | 69.7 |
| LODDS4 | 1,578 (2.8) | 7.70 (6.80–8.70) | 48.8 |
| LODDS5 | 2,144 (3.8) | 11.00 (9.80–12.35) | 35.6 |
| LODDS, Persiani et al. (24) | |||
| LODDS1 | 24,983 (44.0) | 1.00 (Reference) | 88.2 |
| LODDS2 | 21,423 (37.8) | 1.97 (1.88–2.06) | 77.9 |
| LODDS3 | 10,341 (18.2) | 4.81 (4.60–5.02) | 53.6 |
N, number; OR, Odds Ratio; 95% CI, 95% confidence interval; LNR, lymph node ratio; LODDS, log odds of positive lymph nodes; AJCC, American Joint Committee on Cancer.